Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06DCL
|
||||
| Former ID |
DCL000157
|
||||
| Drug Name |
LY335979
|
||||
| Synonyms |
Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] | Discontinued in Phase 3 | [545874] | ||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Eli Lilly
|
||||
| Formula |
C32H34Cl3F2N3O2
|
||||
| Canonical SMILES |
C1CN(CCN1CC(COC2=CC=CC3=C2C=CC=N3)O)C4C5=CC=CC=C5C6C(C6<br />(F)F)C7=CC=CC=C47.Cl.Cl.Cl
|
||||
| InChI |
1S/C32H31F2N3O2.3ClH/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27;;;/h1-14,21,29-31,38H,15-20H2;3*1H/t21-,29-,30+,31?;;;/m1.../s1
|
||||
| InChIKey |
ZPFVQKPWGDRLHL-ZLYBXYBFSA-N
|
||||
| CAS Number |
CAS 167465-36-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
12014959, 14789967, 14936766, 46230217, 47208044, 50605721, 57347952, 99437179, 104437742, 125164087, 126671450, 131480893, 134338836, 135109630, 136340254, 136367440, 137249275, 152258808, 160647659, 160702421, 162011417, 162011631, 162037624, 162205163, 163907968, 170465595, 172080084, 174527858, 179322739, 184817594, 198952861, 223661255, 249814541, 251963144, 251971413, 252158852, 252814002
|
||||
| Target and Pathway | |||||
| Target(s) | Multidrug resistance protein 1 | Target Info | Modulator | ||
| Multidrug resistance protein 3 | Target Info | Modulator | |||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| TCR Signaling Pathway | |||||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | ||||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Abacavir transport and metabolism | |||||
| Multi Drug Resistance Protein 1 (Glycoprotein 1) Regulation | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Allograft Rejection | |||||
| Drug Induction of Bile Acid Pathway | |||||
| Codeine and Morphine MetabolismWP299:Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Farnesoid X Receptor Pathway | |||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| References | |||||